Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Irish Pharmaceutical Healthcare Association naming Muiris O’Connor .
Filed returns
14
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry perspectives on access, innovation and coordination. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Medicines Shortage - Provision in proposed EU General Pharmaceutical Legislation regarding medicines shortages prevention plan. (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | Industry position on a National Life Sciences Strategy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2026 | Irish Pharmaceutical Healthcare Association | Health | (i) IPHA priorities for EU Presidency and (ii) EU Presidency Events (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) | 8 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation, particularly items relating to incentives/intellectual property rights; (ii) EU wide access to new medicines. (Legislation) | 10 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | WTO TRIPS Waiver of IP rights (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2021 | Irish Pharmaceutical Healthcare Association | Health | Report on Value of Expenditure on Medicines (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2021 | Irish Pharmaceutical Healthcare Association | Health | EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Irish Pharmaceutical Healthcare Association | Health | Readiness of Ireland to produce and provide cell and gene therapies (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2019 | Irish Pharmaceutical Healthcare Association | Health | To highlight importance of continuity of supply of medicines in Europe post Brexit (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Irish Pharmaceutical Healthcare Association | Health | Originator pharmaceutical industry's preparations for Brexit (Public policy or programme) | 9 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 14 | 100.0% |